Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level
I'm LongbridgeAI, I can summarize articles.Amylyx Pharmaceuticals reported positive Phase 3 LUCIDITY trial data for avexitide, a GLP-1 receptor antagonist targeting post-bariatric hypoglycemia. The drug reduced severe hypoglycemic episodes by 55% compared to placebo and demonstrated a favorable safety profile. Consequently, AMLX stock surged over 35%. The company plans to submit a New Drug Application to the FDA by late 2026, with potential commercial launch in 2027.
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stock is trading higher on Tuesday after the company released highly favorable topline data from its Phase 3 LUCIDITY clinical trial.
Favorable Trial Outcomes
The multicenter study evaluated avexitide, an investigational glucagon-like peptide-1 (GLP-1) receptor antagonist, for patients suffering from post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery.
PBH is a late complication of weight-loss surgery (like gastric bypass) where low blood sugar happens 1 to 3 hours after eating.
The 78-participant trial successfully met its FDA-agreed primary objective.
Treatment with avexitide demonstrated a substantial 55% decrease in the combined rate of Level 2 and Level 3 hypoglycemic episodes over a 16-week period when compared to a placebo.
Read Also: Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities
Secondary Endpoints Achieved
During the study, adult participants were randomized to receive either a daily 90 mg subcutaneous injection of avexitide or a placebo.
The LUCIDITY trial achieved all secondary targets, displaying statistically significant and consistent declines in Level 2 events, which were tracked by continuous glucose monitoring and self-monitoring of blood glucose.
Independently assessed Level 3 events were also meaningfully reduced.
Safety Profile And Regulatory Plans
Avexitide remained generally well-tolerated, showing a favorable safety record that aligns with previous PBH clinical trials.
Most reported adverse events were mild or moderate, with diarrhea and minor injection site reactions being the most frequent. Researchers observed no serious treatment-related adverse events or notable weight changes during the 16-week timeframe.
The company intends to file a New Drug Application with the FDA before the end of 2026, and the company continues to advance preparations for a potential commercial launch of avexitide in 2027.
A 32-week open-label extension and an expanded access program remain ongoing.
Cash, cash equivalents, and short-term investments were $250.8 million at June 30. Based on its current operating plans, Amylyx expects a cash runway into 2028.
AMLX Stock Price Activity: Amylyx Pharmaceuticals shares were up 35.32% at $29.01 during premarket trading Tuesday, according to Benzinga Pro data.
Read Also: Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
Image via Shutterstock/ grinny